AstraZeneca

AstraZeneca Submits EUA for COVID Antibody Prophylaxis

AstraZeneca released a press release today stating that their long-acting antibody (LAAB) combination, AZD7442, has been shown to reduce the risk of symptomatic Covid-19 by 77% in a clinical trial. The trial included many participants who had medical conditions placing them at greater risk of severe illness and those who had not been producing sufficient antibodies after vaccination.

Read More »

Antibody Development Following COVID Vaccine in Autoimmune Disease Patients

A study coming from the Netherlands looks at the immune response following COVID-19 vaccination in patients with autoimmune disease, focusing specifically on the effects of different immunosuppressive drugs on antibody development. Researchers used serum samples from 289 patients without autoimmune disease, who served as the control group, and 632 patients with autoimmune disease (including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematous and multiple sclerosis). The mean age of participants was 63 years and 57% of participants were female.

Read More »

COVID Vaccination in Patients with SLE

Patients with systemic lupus erythematous (SLE) were excluded from COVID-19 vaccine trials. To better understand the tolerability of COVID-19 vaccines amongst patients with SLE, the international vaccination against COVID in systemic lupus (VACOLUP) study was initiated via online survey. Participants included those with a self-reported, medically confirmed diagnosis of SLE.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.